English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
हिन्दी
日本語
Eli Lilly significantly slashed its guidance for full-year earnings on the back of acquisitions.
Dreamstime
Eli Lilly
shares were falling Thursday after the drugmaker significantly slashed its full-year earnings guidance as a result of its deal spree.
Lilly (ticker: LLY) reported earnings of 10 cents a share on revenue of $9.5 billion in the third quarter. Analysts surveyed by FactSet has expected the company to post a loss of 18 cents a share on revenue just shy of $9 billion.
What’s disappointing was the outlook. Lilly slashed its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.
The company said the reduced outlook was largely due to in-process research and development charges acquired in the third quarter as a result of Lilly’s deals to buy of DICE Therapeutics, Versanis Bio, and Emergence Therapeutics.
Shares in Lilly tumbled 1.7% in premarket trading Thursday, having previously hovered 2% higher before earnings on the back of strong results from peer
Novo Nordisk
(NVO).
Write to Jack Denton at [email protected]
Read the full article here